Trial Profile

A Phase I Trial of BLU-263 in Healthy Volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elenestinib (Primary)
Indications Systemic mastocytosis
Focus Adverse reactions; Pharmacokinetics
Sponsors Blueprint Medicines

Most Recent Events

17 Jun 2021 Results assessing safety, tolerability, and pharmacokinetics of BLU-263 in normal healthy volunteers, presented at the 26th Congress of the European Haematology Association.
11 Apr 2021 According to a Blueprint Medicines media release, data from this study was presented at the American Association for Cancer Research (AACR) Annual Meeting 2021.
11 Apr 2021 Results published in the Blueprint Medicines media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com